Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma

Leuk Lymphoma. 2015 Mar;56(3):785-8. doi: 10.3109/10428194.2014.928936. Epub 2014 Jun 25.

Authors

Saori Maegawa¹, Junya Kuroda, Tsutomu Kobayashi, Shinichi Fuchida, Eri Kawata, Yuri Kamitsuji, Yasuhiko Tsutsumi, Toshiki Iwai, Mitsushige Nakao, Hiroto Kaneko, Nobuhiko Uoshima, Chihiro Shimazaki, Yutaka Kobayashi, Shigeo Horiike, Aihiro Yamamoto, Yutaka Kawahito, Masafumi Taniwaki

Affiliation

¹ Division of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto , Japan.

PMID: 24884317
DOI: 10.3109/10428194.2014.928936

No abstract available

Publication types

Letter

MeSH terms

Aged
Antimetabolites, Antineoplastic / therapeutic use
Arthritis, Rheumatoid / complications*
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / pathology
Autoimmune Diseases / complications*
Autoimmune Diseases / drug therapy
Autoimmune Diseases / pathology
Disease-Free Survival
Female
Humans
Japan
Lymphoma, Large B-Cell, Diffuse / complications*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Methotrexate / therapeutic use
Middle Aged
Prognosis
Remission Induction
Retrospective Studies
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Methotrexate